Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of Sisunatovir Effect on QTc Interval in Healthy Adults
NCT05878522Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sisunatovir in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Pfizer. Primary endpoint: Placebo-Adjusted Change From Baseline in QT Interval Corrected Using Fridericia's Formula at Expected Maximum Concentration at Day 3. Started May 2023; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05878522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05878522.